High end, cutting edge and hard core - this is the first impression of many people on the biomedical industry.
As one of the three leading industries in Shanghai, the scale of Shanghai's biomedical industry is expected to exceed 700 billion yuan in 2021, including 171.2 billion yuan of manufacturing output value, a comparable increase of 12%. Facing the "14th five year plan", Shanghai "medicine" will go to a higher level.
The newly released 14th five year plan for the development of Shanghai biomedical industry (hereinafter referred to as the plan) clearly states that Shanghai will aim at the development direction of "high-end, intelligent and international" of biomedical industry and deeply implement the action of "Zhangjiang R & D + made in Shanghai", Accelerate the building of an innovation highland of biomedical industry with global influence and a world-class biomedical industry cluster.
target: the industrial scale will exceed 100 billion yuan by 2025
The plan proposes that by 2025, the development level of Shanghai biomedical industry will be significantly improved, the leading role in the coordinated development of biomedical industry in the Yangtze River Delta will be more prominent, the international influence of industrial technology innovation sources will continue to increase, and Shanghai will initially be built into the core bearing place of world-class biomedical industry clusters.
industrial growth accelerated. the scale of the city's biomedical industry has exceeded 100 billion yuan, of which the output value of manufacturing industry has reached 240 billion yuan; Build 25 varieties with annual sales of more than 1 billion yuan.
industrial space expanded. launched a total of 26000 mu of available space and built six 10 billion industrial parks.
improve the innovation level. During the 14th Five Year Plan period, 15 and 35 domestic class 1 innovative drugs and Innovation Medical Management Co.Ltd(002173) devices were listed respectively, the R & D investment of Industrial Enterprises above Designated Size accounted for more than 8% of their operating revenue, and the number of invention patent applications of industrial enterprises per 100 million yuan of main revenue reached more than 10.
gathering of outstanding enterprises. it has about 4 pharmaceutical manufacturing enterprises with an annual sales revenue of more than 10 billion yuan, 3 of the top 50 global pharmaceutical and medical device enterprises, and 25 newly listed enterprises.
Focusing on the industrial development goals, Shanghai will implement five actions, including improving the ability of innovative policy sources, expanding industrial clusters, transforming innovative achievements, in-depth integration of industry and medicine and creating a good industrial ecology.
Focusing on the above actions, Shanghai should carry out ten major projects, including the construction of major basic scientific research platforms, tackling key industrial core technologies, the construction of innovative service carriers, the reinforcement and strengthening of industrial chains, the value improvement project of advantageous enterprises, the improvement of advanced manufacturing level, the improvement of clinical transformation capacity, the promotion of innovative products, the optimization of industrial access services and the combination of industry and finance.
deepen the layout of "1 + 5 + X" biomedical industrial park
Liu Ping, deputy director of Shanghai Economic and Information Technology Commission, said that in the next step, Shanghai will layout the biomedical industry from two aspects of industry and space.
in terms of the focus of industrial development, the plan proposes that during the 14th Five Year Plan period, Shanghai will focus on six industries, including high-end biological products, innovative chemical drugs and preparations, modern traditional Chinese medicine, high-end medical devices, technical services and pharmaceutical circulation.
At the same time, Shanghai will also become the core of the cell therapy industry, the main source of global metabolic drugs, such as Alzheimer's disease and diabetes, the next generation of high-end medical devices and innovative products.
From the perspective of spatial layout, the plan proposes that during the 14th Five Year Plan period, Shanghai will continue to deepen the spatial layout of biomedical industry with "1 + 5 + X" as the main body, and improve the integrated layout and innovative development ability of "Zhangjiang R & D + made in Shanghai".
Among them, "1" represents Zhangjiang biomedical innovation leading core area, which will focus on the R & D and transformation of innovative drugs, high-end medical devices and biotechnology services into manufacturing industry chain. "5" represents five characteristic industrial areas, including Lingang New film area, precision medicine first demonstration area, Oriental Meigu life and health integration development area, Gold Coast modern pharmaceutical green bearing area, North Shanghai biomedical high-end manufacturing cluster area and South Hongqiao intelligent medical innovation pilot area. "X" represents the carrier of characteristic industries.
It is reported that during the 13th Five Year Plan period, "1 + 5 + X" biomedical industrial park gathered more than 80% of Shanghai's biomedical industry and contributed 80% of the manufacturing output value.
Liu Ping said that during the "14th five year plan" period, Shanghai will continue to deepen the "1 + 5 + X" layout, form a spatial layout with clear positioning, distinctive characteristics, complete supporting facilities and green ecology, and enhance the influence of the development of Shanghai's biomedical industry through unified planning and layout, environmental protection management, production plants, infrastructure and public services.
